Moxalactam Therapy for Bacterial Infections

Drew J. Winston, Ronald W. Busuttil, Terrance O. Kurtz, Lowell S. Young

Research output: Contribution to journalArticlepeer-review

42 Scopus citations


Moxalactam, a novel β-lactam antimicrobial agent in which oxygen has replaced sulfur in the six-membered ring of the conventional cephem nucleus, has in vitro activity against almost all commonly isolated bacterial pathogens including Staphylococcus aureus, the Enterobacteriaceae, Pseudomonas aeruginosa, Bacteroides fragilis, and Haemophilus influenzae. The clinical efficacy and toxicity of moxalactam alone was evaluated in the treatment of 100 infections, including 22 septicemias. Thirty-two infections involved P aeruginosa, while organisms resistant to one or more of the currently available cephalosporins or cefoxitin were isolated from cultures in 63 of the cases. The overall clinical response was favorable (infection cured or improved) in 86% of the infections. A child with Klebsiella pneumoniae ventriculitis and meningitis was cured with intravenous moxalactam alone. Six of 14 treatment failures involved P aeruginosa, and P aeruginosa isolates resistant to moxalactam emerged during therapy of 12 infections. Side effects, usually mild diarrhea, occurred in only 8.8% of the patients. Except for some severe P aeruginosa infections outside the urinary tract, moxalactam is effective and safe single-agent therapy for infections caused by susceptible organisms and represents a major advancement in β-lactam antimicrobial therapy.

Original languageEnglish (US)
Pages (from-to)1607-1612
Number of pages6
JournalArchives of Internal Medicine
Issue number12
StatePublished - Nov 1981

ASJC Scopus subject areas

  • Internal Medicine


Dive into the research topics of 'Moxalactam Therapy for Bacterial Infections'. Together they form a unique fingerprint.

Cite this